Sioux Falls, SD: OmegaQuant announced in a press release that its Omega-3 Index and Prenatal DHA test kits are now registered in the EU as in vitro diagnostic medical devices. Both tests are also CE-marked. OmegaQuant explained that CE marking is the medical device manufacturer’s claim that a product meets the essential requirements of all relevant European Medical Device Directives outlining the safety and performance requirements for medical devices in the EU.
OmegaQuant is partnering with the Nutritional Analytical Service (NAS) at the Institute of Aquaculture at the University of Stirling in Scotland, to carry out the analysis of omega-3 tests from European consumers. Jason Polreis, CEO of OmegaQuant, explained that the partnership enables OmegaQuant to offer “the same accurate, precise and scientifically validated methods at our three laboratories covering North America, Asia-Pacific and now Europe.”
Polreis added, “We have had clients ask how they can get our omega-3 test panels in Europe and this will now allow us to service them and provide results in a timelier manner. We are looking forward to bringing an at-home collection kit to the EU market to make access to the Omega-3 Index and Prenatal DHA tests convenient, so individuals can personalize their omega-3 intake.”
James Dick, NAS technical manager, added: “We are delighted to work with OmegaQuant to provide this important service to their European customers. This partnership recognizes the internationally renowned expertise of both partners in testing for omega-3 fatty acids and we are looking forward to developing this exciting new partnership.”